tbuckley/cabot-search huggingface dataset:
Collagenase-modified polydopamine nanoparticles for safe and effective vitreolysis
Authors: An-Katrien Minnaert, Van-Phuc Nguyen, Aranit Harizaj, Ilia Goemaere, Bart Van Puyvelde, Maarten Dhaenens, Félix Sauvage, Dieter Deforce, Stefano Salmaso, Paolo Caliceti, Kevin Braeckmans, Karen Peynshaert, Yannis M Paulus, Stefaan C De Smedt, Katrien Remaut
Journal: Journal of Controlled Release (2025)
Lipid nanoparticles target neutrophils to reduce SARS-CoV-2-induced lung injury and inflammation
Authors: Ha Eun Shin, Stefanos Giannakopoulos, Joo Dong Park, Hye Jung Jang, Chun Gwon Park, Sean V Murphy, Juwon Park, Saguna Verma, Wooram Park
Journal: Journal of Controlled Release (2025)
Relieve the suffering: palliative care for the next decade
Authors: William E Rosa, Stephen Connor, Ghauri Aggarwal, Samy Alsirafy, Joanne Brennan, Helena Davies, Julia Downing, Betty Ferrell, Richard Harding, Felicia Marie Knaul, Emmanuel B K Luyirika, María M Marroquín, Joan Marston, Lukas Radbruch, M R Rajagopal, Libby Sallnow, Eric L Krakauer
Journal: The Lancet (2025)
Community-based heat adaptation interventions for improving heat literacy, behaviours, and health outcomes: a systematic review
Authors: Hamimatunnisa Johar, Fatima Ibrahim Abdulsalam, Yuming Guo, Till Baernighausen, Nowrozy Kamar Jahan, Jessica Watterson, Karin Leder, Darwin Gouwanda, G R Letchuman Ramanathan, Kenneth Kwing Chin Lee, Norlen Mohamed, Thahirahtul Asma' Zakaria, Sandra Barteit, Tin Tin Su
Journal: The Lancet Planetary Health (2025)
Efficacy of dietary interventions in irritable bowel syndrome: a systematic review and network meta-analysis
Authors: Melanie S Cuffe, Heidi M Staudacher, Imran Aziz, Enrique Coss Adame, Claudia Krieger-Grubel, Ana Maria Madrid, Bodil Ohlsson, Christopher J Black, Alexander C Ford
Journal: The Lancet. Gastroenterology & hepatology (2025)
Diagnostic accuracy of Truenat MTB Ultima on sputum for pulmonary TB diagnosis in an HIV-endemic setting
Authors: Shima M Abdulgader, Arthur M Chiwaya, Welile V Nwamba, Byron Wp Reeve, Zaida Palmer, Hridesh Mishra, Desiree Mbu, Nondumiso Lushozi, Zola Nkwanyana, Morten Ruhwald, Adam Penn-Nicholson, Robin Warren, Grant Theron
Journal: Clinical Microbiology and Infection (2025)
In vivo programming of adult pericytes aids axon regeneration by providing cellular bridges for SCI repair
Authors: Wenjing Sun, Elliot Dion, Fabio Laredo, Allyson Okonak, Jesse A Sepeda, Esraa Haykal, Min Zhou, Heithem M El-Hodiri, Andy J Fischer, Jerry Silver, Juan Peng, Andrew Sas, Andrea Tedeschi
Journal: Molecular Therapy (2025)

Pericytes are contractile cells of the microcirculation that participate in wound healing after spinal cord injury (SCI). Thus far, the extent to which pericytes cause or contribute to axon growth and regeneration failure after SCI remains controversial. Here, we found that SCI leads to profound changes in vasculature architecture and pericyte coverage. We demonstrated that pericytes constrain sensory axons on their surface, causing detrimental structural and functional changes in adult DRG neurons that contribute to axon regeneration failure after SCI. Perhaps more excitingly, we discovered that in vivo programming of adult pericytes via local administration of platelet-derived growth factor BB (PDGF-BB) effectively promotes axon regeneration and recovery of hindlimb function by contributing to the formation of cellular bridges that span the lesion. Ultrastructural analysis showed that PDGF-BB induced fibronectin fibril alignment and extension, effectively converting adult pericytes into a permissive substrate for axon growth. In addition, PDGF-BB localized delivery positively affects the physical and chemical nature of the lesion environment, thereby creating more favorable conditions for SCI repair. Thus, therapeutic manipulation rather than wholesale ablation of pericytes can be exploited to prime axon regeneration and SCI repair.
Intravitreal adenine base editing of RS1 improves vision in a preclinical mouse model of retinoschisis
Authors: Dong Hyun Jo, Hyewon Jang, Chang Sik Cho, Seok Jae Lee, Ji Hwa Heo, Jung Ah Kim, Se Jin Kim, WonHyoung Ryu, Chan-Wook Park, Byeong-Cheol Kang, Heon Yung Gee, Young Hoon Sung, Hyongbum Henry Kim, Jeong Hun Kim
Journal: Molecular Therapy (2025)
Müller cells trophism and pathology as the next therapeutic targets for retinal diseases.
Authors: Alessandro Arrigo, Ottavio Cremona, Emanuela Aragona, Filippo Casoni, Giacomo Consalez, Rüya Merve Dogru, Stefanie M Hauck, Alessio Antropoli, Lorenzo Bianco, Maurizio Battaglia Parodi, Francesco Bandello, Antje Grosche
Journal: Progress in Retinal and Eye Research (2025)
Enhanced CAR-T Function and Mitochondrial Fitness from Earlier Unfractionated Stem Cell Product in Multiple Myeloma
Authors: Ciara L Freeman, Julieta Abraham-Miranda, Meghan Menges, Reginald M Atkins, Jerald Noble, Hien Liu, Salvatore Corallo, Luis A Cuadrado Delgado, Albert J Ribickas, Constanza Savid-Frontera, Gabriel de Avila, Omar A Castaneda Puglianini, Jose Ochoa-Bayona, Doris K Hansen, Melissa Alsina, Rachid Baz, Taiga Nishihori, Kenneth H Shain, Frederick L Locke
Journal: Molecular Therapy (2025)
Risk Factors for Patient-Important Upper Gastrointestinal Bleeding
Authors: Adam M. Deane, François Lauzier, Neill K. J. Adhikari, François Lamontagne, Diane Heels-Ansdell, Lehana Thabane, David Williamson, Salmaan Kanji, Jeffrey F. Barletta, Simon Finfer, Yaseen Arabi, Marlies Ostermann, John C. Marshall, Nicole L. Zytaruk, Miranda Hardie, Naomi E Hammond, Gordon Guyatt, Kyle C. White, Karen E. A. Burns, Joanna C Dionne, Paul J. Young, Deborah J. Cook
Journal: American Journal of Respiratory and Critical Care Medicine (2025)

Patient-important gastrointestinal bleeding is an endpoint developed by patients and family members; however, risk factors for this outcome are unknown. To identify risk factors for patient-important upper gastrointestinal bleeding among invasively ventilated adults. This pre-planned regression analysis of an international trial database evaluated baseline and time-varying risk factors in the preceding 3 days for patient-important upper gastrointestinal bleeding, accounting for illness severity and the competing risk of death. Patient-important upper gastrointestinal bleeding occurred in the ICU among 131 of 4,821 (2.7%) patients. Baseline APACHE II score (Hazard Ratio [HR] 1.24 [95%CI 1.12, 1.37] per 5-point increase), and the following were associated with greater risk of patient-important bleeding: inotropes or vasopressors (HR 2.05 [1.35, 3.12]), severe thrombocytopenia (platelet count <50 × 109/L) (HR 2.21 [1.24, 3.94]) and platelet inhibitor drugs (HR 1.69 [1.11, 2.56]). A lower bleeding risk was associated with pantoprazole (HR 0.36 [0.25, 0.54]) and enteral nutrition (HR 0.81 [0.68, 0.97]) for every 500 mL/day increase. There was no interaction between enteral nutrition and pantoprazole (interaction p value=0.94). Allocation to pantoprazole was associated with a lower risk of patient-important upper gastrointestinal bleeding irrespective of the volume of enteral nutrition (HR 0.36 [0.22, 0.58] for 500ml/day, and HR 0.36 [0.18, 0.72] for no enteral nutrition). The association of enteral nutrition and bleeding was similar with pantoprazole (HR 0.82 [0.63, 1.07]) or without pantoprazole (HR 0.81 [0.66, 1.00]). Several factors are associated with the risk of patient-important upper gastrointestinal bleeding during invasive ventilation.
Quantification of Perivascular Adipose Tissue Attenuation Does not Add Incremental Prognostic Value in Patients Undergoing Transcatheter Aortic Valve Implantation
Authors: Carolina Donà, Noemi Pavo, Adriana Vinzens, Pimrapat Gebert, Dietrich Beitzke, Lukas Reider, Nidaa Mikail, Alexia Rossi, Katharina Mascherbauer, Susan Bengs, Achi Haider, Ronny R Buechel, Philipp E Bartko, Christian Loewe, Julia Mascherbauer, Christian Hengstenberg, Georg Goliasch, Max Paul Winter, Catherine Gebhard
Journal:  (2025)

Perivascular adipose tissue attenuation (PVAT) has emerged as a novel coronary computed tomography angiography (CCTA)-based biomarker predicting cardiovascular events by capturing inflammation around the coronary arteries. We assessed whether PVAT adds incremental prognostic value in patients undergoing transcatheter aortic valve implantation (TAVI). A total of 510 patients underwent CCTA imaging prior to TAVI between November 2015 and June 2020 at the Medical University of Vienna. PVAT was obtained from CCTA images and was measured around the right coronary artery [PVAT(RCA)] and the aortic valve [PVAT(valve)]. Following application of exclusion criteria, 372 patients [mean age 80.6 ± 6.8 years; 169 (45%) women] were analysed. Over a median follow-up of 3.0 (IQR 2.5-3.6) years, 52 (14%) individuals experienced a major adverse cardiovascular event (MACE, a composite of non-fatal stroke or myocardial infarction, cardiac death, or vascular intervention). Individuals exhibiting elevated PVAT[valve] displayed a heightened surgical risk according to European System for Cardiac Operative Risk Evaluation II, a lower body mass index, reduced left ventricular ejection fraction, prolonged hospitalization following TAVI, and elevated levels of circulating inflammatory markers compared with those in the low PVAT[valve] group (P < 0.05). However, neither PVAT[valve] nor PVAT[RCA] were independently associated with the occurrence of MACE in adjusted multi-variable analyses (PVAT[valve]: sub-distribution hazard ratio [SHR] 1.14, 95% CI:0.63-2.05, P = 0.672); PVAT[RCA]: SHR 1.16 [95% CI: 0.81-1.66], P = 0.417). Measuring PVAT around either the right coronary artery or the aortic valve does not provide additional prognostic value beyond established risk factors for the prediction of MACE in patients undergoing TAVI.
Cardiovascular Adverse Events and Associated Costs of CDK4/6 Inhibitors in Patients With Breast Cancer
Authors: Chanhyun Park, Yi-Shao Liu, Ahmed S. Kenawy, Yuan-Han Lin, Yan Liu, Ji Haeng Heo
Journal: Journal of the National Comprehensive Cancer Network (2025)

Background: Cardiotoxicity and cardiovascular (CV) adverse events associated with CDK4/6 inhibitors have raised concerns in the treatment of advanced breast cancer, impacting patient safety and increasing health care costs. This study compares the incidence of hypertension and major adverse cardiovascular events (MACE) in patients with breast cancer receiving CDK4/6 inhibitors and estimates the incremental health care costs associated with these conditions. Methods: This retrospective cohort study utilized the 2017–2021 Merative MarketScan Research Database. Women with breast cancer who initiated CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) were included in 2 cohorts. The hypertension cohort comprised patients with no prior hypertension in the 12 months before initiating CDK4/6 inhibitors, whereas the MACE cohort included those with no prior hypertension or MACE during the same period. The primary outcomes were the incidence of hypertension and MACE, with secondary outcomes being the incremental health care costs associated with these conditions. Results: A total of 2,780 patients were included in the hypertension cohort and 2,043 in the MACE cohort. Compared with ribociclib, neither abemaciclib (hazard ratio [HR], 0.791; 95% CI, 0.507–1.232) nor palbociclib (HR, 0.723; 95% CI, 0.493–1.060) showed a statistically significant difference in hypertension risk. For MACE, palbociclib was associated with a statistically significant lower risk (HR, 0.636; 95% CI, 0.454–0.892), whereas abemaciclib was not (HR, 0.795; 95% CI, 0.540–1.169). Patients who developed hypertension and MACE incurred higher health care costs, averaging $2,964 and $4,010 per patient per month, respectively. Conclusions: Palbociclib was associated with a significantly lower risk of MACE compared with ribociclib in patients with breast cancer. Patients who developed hypertension or MACE incurred substantially higher health care costs. These findings underscore the importance of minimizing CV adverse events in patients with breast cancer treated with CDK4/6 inhibitors.
Outcome Measures for Interdisciplinary Care in Immune-mediated Inflammatory Skin Diseases (skIMIDs): A Scoping Review
Authors: Laure Lemarcq, Valerie Reynaert, Ellen Van den Steen, Corinne Evers-Lebrun, Branka Marinović, Diederik De Cock, Jan Gutermuth
Journal: British Journal of Dermatology (2025)

Abstract Background There is a growing trend towards interdisciplinary care (IC) for the management of immune-mediated inflammatory skin diseases (skIMIDs). However, an overview of instruments used to evaluate whether IC is superior to usual care is currently lacking. Objective This scoping review aims to gain insight into clinician- and patient-reported outcome measures (ClinROMs and PROMs) used in IC for skIMIDs. Methods A comprehensive literature search was conducted by screening PubMed, Web of Science, and Embase databases from their inception until October 2024. Eligible studies had to investigate IC for skIMIDs involving dermatologists, and report either ClinROMs or PROMs. Two independent reviewers screened all records by title, abstract, and full text, with conflicts resolved by a third reviewer. Results Fourteen studies were included in this review. Nine investigated IC for psoriasis (PsO), four for atopic dermatitis (AD), and one for hidradenitis suppurativa. Six PsO studies examined combined dermatology-rheumatology clinics, while four studies explored collaborations with psychiatrists or psychologists for PsO or AD. The remaining IC models were diverse. A total of 49 different ClinROMs and PROMs were reported across the included studies, with 38 being reported by only one study. Except for the Dermatology Life Quality Index (DLQI, used by 12 studies), Body Surface Area (BSA, used by four studies), Psoriasis Area Severity Index (PASI, used by all PsO studies), and Eczema Area and Severity Index or Scoring Atopic Dermatitis Index (EASI or SCORAD Index, used by all AD studies), the reported ClinROMs and particularly PROMs vary widely. Conclusion Although several studies describe IC models for skIMIDs, few investigated their impact on ClinROMs or PROMs. The heterogeneous outcomes used pose a challenge for comparison across studies. This review highlights the need for consensus on a core set of outcome measures for IC in skIMIDs to create a common language among the health care providers involved, and enhance comparability between studies. Implementing standardised outcome measures for IC in skIMIDs could contribute to the development of evidence-based guidelines, and ultimately, improve patient care.
Outcome measurement in pemphigus clinical research: a scoping review on heterogeneity in outcome reporting and definitions
Authors: Marjolein A J Hiel, Eva W H Korte, Billal Tedbirt, Marieke C Bolling, Joost M Meijer, Phyllis I Spuls, Sjoukje van der Werf, Marc Yale, Barbara Horváth, Pascal Joly
Journal: British Journal of Dermatology (2025)

Abstract Background Pemphigus is an autoimmune bullous disease (AIBD) and has two main subtypes: pemphigus vulgaris (PV) and pemphigus foliaceus (PF). For adequate interpretation and comparison of clinical studies in pemphigus, it is essential to have outcomes and outcome measurement instruments (OMIs) that are well-defined, uniform, and relevant. Objective To provide a comprehensive overview of previously reported outcomes and OMIs in pemphigus clinical research over the past two decades. Methods A systematic literature search was performed in the databases MEDLINE, EMBASE, CINAHL, PsycINFO, Cochrane CENTRAL, Web of Science and trial registries covering the period between January 2002 and December 2023. Clinical trials, prospective cohort studies and systematic reviews were included. Retrospective studies were excluded. All identified outcomes and their respective OMIs were grouped into outcome domains and areas. Results From all the included studies (n=205), a total of 1,502 outcomes were extracted verbatim, categorized in 55 outcome domains and 11 outcome areas. We found a gradual increase in the number of published trials over the past two decades. The included studies mainly focused on “clinical response” (92%), “safety monitoring” (75%) and “immune response” (61%). “Quality of life” was sparsely reported (12%). Heterogeneity of reported outcomes was observed across all study designs. Within the outcome area “clinical response”, the proportion of defined outcomes based on the 2008 consensus statement has not been consistent over time. However, four recent clinical trials used primary endpoints based on the 2008 consensus definitions. Moreover, a broad spectrum of outcome measurement instruments (n=65) was reported. Conclusions This review showed a wide variety in reported outcomes and OMIs in pemphigus clinical research over the past two decades. Despite standardization efforts, most studies still lack well-defined, consistent, and relevant outcomes and OMIs. However, a positive trend is emerging as four recent trials did use consensus-based definitions and patient-focused OMIs. Nevertheless, the outcomes are overly stringent, lack patient-centeredness, and do not include intermediate endpoints. Therefore, refinement of the 2008 expert consensus statement through collaborative efforts of all stakeholders is essential to promote uniformity in future pemphigus outcome measurement and advancing pemphigus drug development.
Claim Denials for Cancer-Related Next-Generation Sequencing in Medicare
Authors: So-Yeon Kang, Ilina Odouard, Carole Roan Gresenz
Journal: JAMA Network Open (2025)

Importance The Centers for Medicare &amp;amp;amp; Medicaid Services implemented a National Coverage Determination (NCD) for genetic testing using next-generation sequencing (NGS) in March 2018 and amended it in January 2020. Little is known about how often NGS insurance claims are denied and what factors are associated with these denials. Objective To examine the prevalence of and factors associated with claim denials for NGS testing among Medicare enrollees. Design, Setting, and Participants This cohort study used a 20% random sample of Medicare claims data from January 1, 2016, to December 31, 2021. Statistical analysis took place from June to October 2024. Main Outcomes and Measures Claim denials were measured based on payment and denial data. Multivariable logistic regression models were estimated with patient and claim characteristics, including testing type, testing site, and time period indicators reflecting the presence and scope of the NCD: no NCD (period 1), first NCD (period 2), and amended NCD (period 3). Results The study sample included 29 919 cancer-related NGS claims among 24 443 unique Medicare beneficiaries (51.8% males; 44.7% aged &amp;amp;gt;75 years). The number of cancer-related NGS testing claims increased from 1912 in 2016 to 9177 in 2021. Claim denial occurred among 23.3% of the NGS claims in the sample. The claim denial rate was 16.8% before the NCD, 20.3% after the implementation of the NCD in 2018, and 27.4% after the amended NCD in 2020. Claims for NGS testing were more likely to be denied if they were performed in independent laboratories (odds ratio [OR], 2.76 [95% CI, 2.58-2.95]; P &amp;amp;lt; .001) or other nonhospital sites (OR, 2.55 [95% CI, 2.12-3.07]; P &amp;amp;lt; .001) vs a hospital or if they were for 50 or more genes vs 50 or fewer genes for solid tumors (OR, 1.32 [95% CI, 1.23-1.43]; P &amp;amp;lt; .001). The likelihood of a claim denial was higher in both time periods after the original 2018 NCD compared with before the NCD (period 2: OR, 1.23 [95% CI, 1.10-1.36]; P &amp;amp;lt; .001; period 3: OR, 1.64 [95% CI, 1.49-1.80]; P &amp;amp;lt; .001). The claim denial likelihood for period 3 was significantly higher than period 2 (OR, 1.34 [95% CI, 1.24-1.44]; P &amp;amp;lt; .001). Conclusions and Relevance In this cohort study of cancer-related NGS testing claims among Medicare enrollees, denial rates varied by testing type and testing site and increased over time. The findings suggest the continued existence of uncertainty regarding coverage for NGS, despite the NCD. Policy approaches to further reduce uncertainty regarding NGS coverage and raise awareness of potential financial liability warrant consideration.
Cost-Effectiveness of Left Ventricular Assist Device for Transplant-Ineligible Patients
Authors: Elisabeth M. Schaffer, Rebecca Giok Sim Su, Junxing Chay, Eric A. Finkelstein
Journal: JAMA Network Open (2025)

Importance Singapore is considering subsidizing left ventricular assist devices (LVADs) for end-stage heart failure (ESHF) and uses cost-effectiveness evidence to inform the determination. Yet, no economic evaluation has thus far been conducted. Objective To estimate the lifetime cost-effectiveness of LVAD compared with optimal medical management for transplant-ineligible patients. Design, Setting, and Participants This economic evaluation used a Markov model to simulate survival, stroke incidence, other adverse events, and heart failure hospitalizations for a cohort of adult patients in Singapore with transplant-ineligible ESHF, most of whom were inotrope dependent. Latest LVAD mortality data from a randomized clinical trial were age-adjusted, and an indirect comparison of prior trial results was performed to estimate survival for inotrope-dependent and inotrope-independent patients. Costs were estimated (in 2023 Singapore dollars [SGD]) using cohort billing data from 2017 to 2022 and National Heart Centre Singapore LVAD charges. Statistical analysis was performed from December 2023 to July 2024. Exposure HeartMate 3 LVAD (Abbott). Main Outcomes and Measures Health care costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) evaluated against a threshold of SGD 114 000 (US $85 075) per QALY gained. Results At model initiation, the cohort had a mean (SD) age of 64 (12) years, and 78% (range, 68%-86%) of patients were inotrope dependent. In the base case analysis, LVAD yielded an additional 3.45 QALYs at an incremental cost of SGD 404 678 (US $301 999), producing an ICER of SGD 117 370 (US $87 590) per QALY gained for the transplant-ineligible population. The ICER differed for inotrope-use subgroups at SGD 106 458 (US $79 446) per QALY gained for inotrope-dependent patients and SGD 174 798 (US $130 446) per QALY gained for inotrope-independent patients (with 59% and 19% probabilities, respectively, of attaining high value). The inotrope-dependent ICER was sensitive to model input changes and structural assumptions, whereas the inotrope-independent ICER consistently exceeded the high-value threshold in scenario analyses. In threshold analyses, a 44% reduction in the total implantation price or a 54% reduction in the all-cause mortality hazard were required for LVAD to be high value for inotrope-independent patients. Confidence that the inotrope-dependent ICER is high value increased to 75% and 85% with respective 20% and 33% reductions in total implantation price. Conclusions and Relevance In this economic evaluation comparing LVAD with optimal medical management, LVAD was potentially high value for most transplant-ineligible patients who are inotrope dependent. Confidence in this result was improved with plausible price reductions, yet only extreme changes rendered LVAD high value for inotrope-independent patients.